Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

227.00 -4.99 (-2.15%)
Streaming Delayed Price Updated: 10:35 AM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
38 39 Next >
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Thursday
Wedbush boosted Tesla, Inc. (NASDAQ:TSLA) price ... 
Via Benzinga
Biogen inc (BIIB) Q3 2021 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company... 
Via Benzinga
Expert Ratings For Biogen
Over the past 3 months, 13 analysts have published their opinion on Biogen (NASDAQ: 
Via Benzinga
Analyst Ratings For Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the... 
Via Benzinga
Where Biogen Stands With Analysts
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following a... 
Via Benzinga
Biogen CEO Says Alzheimer's Uptake 'Is Delayed,' But Shares Pop On Earnings Beat
Biogen's Alzheimer's drug is facing delayed uptake, but Q3 sales and earnings beat. 
Via Investor's Business Daily
Biogen Posts Just $300K Sales From Aduhelm In Q3, Though Earnings Beat Estimates
Biogen Inc (NASDAQ: BIIB) has posted Q3 adjusted EPS of $4.77 ahead of the consensus estimate of $4.11, but quarterly profit fell around 53% Y/Y to $329.2 million... 
Via Benzinga
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
Earnings Outlook For Biogen
Biogen(NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal. 
Via Investor's Business Daily
Analyst Ratings For Biogen
Over the past 3 months, 10 analysts have published their opinion on Biogen (NASDAQ: 
Via Benzinga
Analyst Ratings For Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the... 
Via Benzinga
Earnings Scheduled For October 20, 2021
Companies Reporting Before The Bell • Canadian Pacific Railway (NYSE:CP) is expected to report quarterly earnings at $0.95 per share on revenue of $2.02 billion.... 
Via Benzinga
Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide... 
Via Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
2 Top Healthcare Stocks That Could Be Bought Out in 2022
These two novel-drug makers could be top takeover targets next year. 
Via The Motley Fool
Exposures COVID-19
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
Why Humana Is Suing Biogen
Biogen continues to deal with the aftermath of allegedly paying co-pays for some Medicare patients. 
Via The Motley Fool
Could Biogen's Blockbuster Hopes for Alzheimer's Disease Drug Aduhelm Be Doomed?
Aduhelm could face yet another hurdle with reports of safety issues. 
Via The Motley Fool
3 Biotech Stocks That Could Make You Richer in October and Beyond
Three Motley Fool contributors think these biotech stocks should be big winners. 
Via The Motley Fool
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
Rising Oil Prices and Yields Makes Market Navigation More Complex
Bitcoin (/BTC) topped $50,000 this morning for the first since May, but traders may be more focused on oil prices and yields. Crude oil (/CL) is continuing its rise... 
Via Benzinga
Exposures Fossil Fuels
See Why Perrigo Shares Are Moving Higher On Thursday
Over-the-counter drugs company Perrigo Company plc (NYSE: 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Benzinga's Bulls And Bears Of The Week: Apple, Bitcoin, Disney, Microsoft And More
Benzinga has examined the prospects for many investor favorite sto... 
Via Benzinga
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
It's been about four months since Biogen, Inc. (NASDAQ:BII... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.